<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Subst Abus</journal-id><journal-id journal-id-type="iso-abbrev">Subst Abus</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Substance abuse</journal-title></journal-title-group><issn pub-type="ppub">0889-7077</issn><issn pub-type="epub">1547-0164</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11044711</article-id><article-id pub-id-type="pmcid-ver">PMC11044711.1</article-id><article-id pub-id-type="pmcaid">11044711</article-id><article-id pub-id-type="pmcaiid">11044711</article-id><article-id pub-id-type="manuscript-id">NIHMS1987391</article-id><article-id pub-id-type="pmid">37702046</article-id><article-id pub-id-type="doi">10.1177/08897077231186216</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1987391</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1987391</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association Between Opioid Dose Reduction Rates and Overdose Among Patients Prescribed Long-Term Opioid Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Glanz</surname><given-names initials="JM">Jason M.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="S">Stanley</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Narwaney</surname><given-names initials="KJ">Komal J.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McClure</surname><given-names initials="DL">David L.</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rinehart</surname><given-names initials="DJ">Deborah J.</given-names></name><degrees>MA, PhD</degrees><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ford</surname><given-names initials="MA">Morgan A.</given-names></name><degrees>MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="AP">Anh P.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8862-8078</contrib-id><name name-style="western"><surname>Binswanger</surname><given-names initials="IA">Ingrid A.</given-names></name><degrees>MD, MPH, MS</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref><xref rid="A8" ref-type="aff">8</xref></contrib></contrib-group><aff id="A1"><label>1</label>Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA</aff><aff id="A2"><label>2</label>Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA</aff><aff id="A3"><label>3</label>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA</aff><aff id="A4"><label>4</label>Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA</aff><aff id="A5"><label>5</label>Center for Health Systems Research, Office of Research, Denver Health and Hospital Authority, Denver, CO, USA</aff><aff id="A6"><label>6</label>Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA</aff><aff id="A7"><label>7</label>Chemical Dependency Treatment Services, Colorado Permanente Medical Group, Aurora, CO, USA</aff><aff id="A8"><label>8</label>Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author contributions</p><p id="P2">JG and IB conceived of this study. JG, SX, KN, DM, DR, and AN contributed to the methods and statistical analyses. JG and IB took the lead in writing this manuscript. All authors, JG, IB, SX, KN, DM, DR, MF, and AN, provided critical feedback and contributed to the writing of the manuscript.</p></fn><corresp id="CR1"><bold>Corresponding Author:</bold> Jason M. Glanz, PhD, Senior Investigator, Institute for Health Research, Kaiser Permanente Colorado, 2550 S. Parker Road, Suite 200, Aurora, CO 80014, USA. <email>Jason.M.Glanz@kp.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>9</month><year>2023</year></pub-date><volume>44</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">460983</issue-id><fpage>209</fpage><lpage>219</lpage><pub-history><event event-type="nihms-submitted"><date><day>23</day><month>04</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>25</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>25</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 19:25:12.460"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><permissions><license><license-p>Article reuse guidelines: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/journals-permissions">sagepub.com/journals-permissions</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1987391.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P3">Tapering long-term opioid therapy is an increasingly common practice, yet rapid opioid dose reductions may increase the risk of overdose. The objective of this study was to compare overdose risk following opioid dose reduction rates of &#8804;10%, 11% to 20%, 21% to 30%, and &gt;30% per month to stable dosing.</p></sec><sec id="S2"><title>Methods:</title><p id="P4">We conducted a retrospective cohort study in three health systems in Colorado and Wisconsin. Participants were patients &#8805;18 years of age prescribed long-term opioid therapy between January 1, 2006, and June 30, 2019. Five opioid dosing patterns and drug overdoses (fatal and nonfatal) were identified using electronic health records, pharmacy records, and the National Death Index. Cox proportional hazard regression was conducted on a propensity score-weighted cohort to estimate adjusted hazard ratios (aHRs) for follow-up periods of 1, 3, 6, 9, and 12 months after a dose reduction.</p></sec><sec id="S3"><title>Results:</title><p id="P5">In a cohort of 17 540 patients receiving long-term opioid therapy, 42.7% of patients experienced a dose reduction. Relative to stable dosing, a dose reduction rate of &gt;30% was associated with an increased risk of overdose and the aHR estimates decreased as the follow-up increased; the aHRs for the 1-, 6- and 12-month follow-ups were 5.33 (95% CI, 1.98&#8211;14.34), 1.81 (95% CI,1.08&#8211;3.03), and 1.49 (95% CI, 0.97&#8211;2.27), respectively. The slower tapering rates were not associated with overdose risk.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P6">Patients receiving long-term opioid therapy exposed to dose reduction rates of &gt;30% per month had increased overdose risk relative to patients exposed to stable dosing. Results support the use of slow dose reductions to minimize the risk of overdose.</p></sec></abstract><kwd-group><kwd>long-term opioid therapy</kwd><kwd>opioid tapering</kwd><kwd>overdose</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>